Physician profile
Michael D Cooper
NPI 1992929137
$11,796.66
in general payments reported to CMS, 2019-2025
38 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,481 · 2020: $393 · 2021: $996 · 2022: $1,985 · 2023: $2,472 · 2024: $1,724 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,874 · Travel and Lodging: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,874.05 |
| Travel and Lodging | $1,069.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,658.27 | 2019-2025 | Mitraclip, Triclip, Pressurewire |
| Edwards Lifesciences Corporation | $1,055.69 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $1,029.03 | 2021-2025 | Watchman Access System, Avvigo Guidance System, Ekosonic |
| Amgen INC. | $840.96 | 2019-2025 | Repatha, Repatha |
| Abiomed | $578.44 | 2019-2025 | Impella |
| Medtronic, INC. | $467.51 | 2021-2025 | Corevalve Evolut R, Biomedicus |
| Novartis Pharmaceuticals Corporation | $465.26 | 2019-2025 | |
| Shockwave Medical, INC | $453.74 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $300.47 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $236.37 | 2019-2024 | Xarelto |
| Pfizer INC. | $205.08 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.73 | 2019-2024 | Lifevest |
| Cardiovascular Systems INC. | $170.92 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $127.36 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.04 | 2019-2024 | Jardiance |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.